Latest filings (excl ownership)
8-K
Avenue Therapeutics Announces Reverse Stock Split
26 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 24
DEF 14C
Information statement
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18 Mar 24
8-K
Other Events
15 Mar 24
PRE 14C
Preliminary information
8 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
8 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
23 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
424B3
Prospectus supplement
2 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
DEF 14C
Information statement
29 Jan 24
UPLOAD
Letter from SEC
29 Jan 24
S-3
Shelf registration
24 Jan 24
PRE 14C
Preliminary information
17 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
12 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 Nov 23
8-K
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
2 Nov 23
424B4
Prospectus supplement with pricing info
2 Nov 23
EFFECT
Notice of effectiveness
1 Nov 23
CORRESP
Correspondence with SEC
30 Oct 23
CORRESP
Correspondence with SEC
30 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
S-1/A
IPO registration (amended)
23 Oct 23
FWP
Free writing prospectus
5 Oct 23
FWP
Free writing prospectus
3 Oct 23
S-1/A
IPO registration (amended)
29 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Sep 23
8-K
Other Events
27 Sep 23
UPLOAD
Letter from SEC
21 Sep 23
S-1
IPO registration
18 Sep 23
8-K
Entry into a Material Definitive Agreement
8 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
Latest ownership filings
SC 13D/A
Fortress Biotech, Inc.
17 Apr 24
4
Change in insider ownership
17 Apr 24
4
Change in insider ownership
3 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
Davidow Robert L
13 Dec 23
4
Robert L Davidow
13 Dec 23
SC 13G
Davidow Robert L
28 Nov 23
3
Robert L Davidow
28 Nov 23
SC 13D/A
Fortress Biotech, Inc.
18 Sep 23
4
LINDSAY A MD ROSENWALD
12 Sep 23
4
Change in insider ownership
12 Sep 23
4
Faith L. Charles
5 Jul 23
4
David Jin
5 Jul 23
4
LINDSAY A MD ROSENWALD
5 Jul 23
4
JAY D KRANZLER
5 Jul 23
4
Curtis Gale Oltmans
5 Jul 23
4
Neil Herskowitz
5 Jul 23
4
Alexandra MacLean
3 Jul 23
4
Change in insider ownership
4 Apr 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13D/A
Fortress Biotech, Inc.
6 Jan 23
4
Change in insider ownership
4 Jan 23
SC 13G
SABBY MANAGEMENT, LLC
4 Jan 23
SC 13G/A
Nantahala Capital Management, LLC
14 Dec 22
SC 13D/A
InvaGen Pharmaceuticals, Inc.
19 Oct 22
SC 13G
CVI Investments, Inc.
17 Oct 22
SC 13G
INTRACOASTAL CAPITAL, LLC
17 Oct 22
4
Change in insider ownership
13 Oct 22
3
Alexandra MacLean
3 Aug 22
SC 13D/A
InvaGen Pharmaceuticals, Inc.
28 Jul 22
3
David Jin
25 May 22
3
Faith L. Charles
17 May 22
SC 13G
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
VANGUARD GROUP INC
9 Feb 22
SC 13G/A
VANGUARD INDEX FUNDS
9 Feb 22
4
JAY D KRANZLER
21 Dec 21
4
Neil Herskowitz
21 Dec 21
4
Curtis Gale Oltmans
21 Dec 21
3
Curtis Gale Oltmans
21 Dec 21
4
Lucy Lu
20 Dec 21